Arrhythmias & electrophysiology
Magnetic Resonance-Guided Stereotactic Radioablation for Septal Ventricular Tachycardias
Authors' conclusion
MRgSTAR represents a safe and effective strategy for treating septal VT.
Study context
- Population
- Patients with septal ventricular tachycardia (VT) substrate (refractory VT)100% male
- Participants
- 11 patients
- Outcome
- Recurrence of any sustained VT beyond the 6-week blanking period
- Follow-up
- Mean 12 ± 6 months
Methodological detailssingle-group, consecutive patients
- Single-group
- Consecutive patients
Main finding
As reported in the abstract
Recurrence of any sustained VT beyond 6-week blanking period
Efficacy outcome occurred
3
27.3%
Observational data: associations, not effects.
Further findings
| Outcome | Values |
|---|---|
| Same-day discharge | MRgSTAR 54.5% |
Implantable cardioverter-defibrillator (ICD) therapy
- ICD therapy before vs after magnetic resonance-guided STAR (MRgSTAR)
- 23.6 vs 1.7; P < 0.001
LVEF
- LVEF before MRgSTAR (median)
- 38% [Q1-Q3: 33.5%-42.0%]
- LVEF after MRgSTAR (median)
- 43.8% [Q1-Q3: 35%-47%]
- Before vs after
- P = 0.04
Safety
- Complications after MRgSTAR
- 0
- Adverse effects in ICD and lead system
- 0
- AV block in 7 patients with preserved AV conduction
- 0
Original publication
Magnetic Resonance-Guided Stereotactic Radioablation for Septal Ventricular Tachycardias. JACC Clin Electrophysiol. Published 9 October 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →